Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1972 1
1973 1
1974 2
1975 9
1976 3
1977 7
1978 5
1979 7
1980 4
1981 3
1982 4
1983 4
1984 1
1985 3
1986 1
1987 1
1988 4
1989 2
1990 2
1991 6
1992 1
1993 5
1994 7
1995 5
1996 3
1997 1
1998 2
1999 7
2000 4
2001 8
2002 4
2003 4
2004 4
2005 3
2006 3
2007 3
2008 6
2009 4
2010 3
2011 4
2012 3
2013 6
2014 3
2015 5
2016 3
2017 1
2018 1
2020 1
2021 3
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

169 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Cunningham AL, et al. Among authors: ahonen a. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Free article. Clinical Trial.
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
Joura EA, Ulied A, Vandermeulen C, Rua Figueroa M, Seppä I, Hernandez Aguado JJ, Ahonen A, Reich O, Virta M, Perino A, Peris Tuser M, Peters K, Origoni M, Raspagliesi F, Tjalma WAA, Tummers P, Woelber L, Nieminen P, van Damme P, Sehouli J, Fiol Ruiz G, Brucker S, Fehm T, Cheon K, Rawat S, Luxembourg A, Wittke F. Joura EA, et al. Among authors: ahonen a. Vaccine. 2021 May 12;39(20):2800-2809. doi: 10.1016/j.vaccine.2021.01.074. Epub 2021 Mar 3. Vaccine. 2021. PMID: 33676783 Clinical Trial.
Clinical audit: Development of the criteria of good practices.
Soimakallio S, Alanen A, Järvinen H, Ahonen A, Ceder K, Lyyra-Laitinen T, Paunio M, Sinervo T, Wigren T. Soimakallio S, et al. Among authors: ahonen a. Radiat Prot Dosimetry. 2011 Sep;147(1-2):30-3. doi: 10.1093/rpd/ncr260. Epub 2011 Oct 6. Radiat Prot Dosimetry. 2011. PMID: 21979432 Review.
[Cardiac sarcoidosis].
Kandolin R, Lehtonen J, Schildt J, Granér M, Salmenkivi K, Ahonen A, Karhumäki L, Kupari M. Kandolin R, et al. Among authors: ahonen a. Duodecim. 2009;125(21):2344-50. Duodecim. 2009. PMID: 19999658 Finnish.
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, Forsten A, Seppa I, Ding J, Neveu D, Jordanov E, Dhingra MS. Piazza FM, et al. Among authors: ahonen a. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-10. doi: 10.1080/21645515.2021.1902701. Epub 2021 Jun 4. Hum Vaccin Immunother. 2022. PMID: 34085900 Free PMC article.
Three-phase bone scintigraphy in chronic epicondylitis.
Pienimäki TT, Takalo RJ, Ahonen AK, Karppinen JI. Pienimäki TT, et al. Among authors: ahonen ak. Arch Phys Med Rehabil. 2008 Nov;89(11):2180-4. doi: 10.1016/j.apmr.2008.04.023. Arch Phys Med Rehabil. 2008. PMID: 18996248
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.
Vesikari T, Brzostek J, Ahonen A, Paassilta M, Majda-Stanislawska E, Szenborn L, Virta M, Clifford R, Jackowska T, Kimmel M, Bindi I, Keshavan P, Pedotti P, Toneatto D. Vesikari T, et al. Among authors: ahonen a. Hum Vaccin Immunother. 2021 Nov 2;17(11):4689-4700. doi: 10.1080/21645515.2021.1968214. Epub 2021 Sep 28. Hum Vaccin Immunother. 2021. PMID: 34582323 Free PMC article. Clinical Trial.
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O. Klein NP, et al. Among authors: ahonen a. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194-201. doi: 10.1093/jpids/piz010. J Pediatric Infect Dis Soc. 2020. PMID: 30849175 Free PMC article. Clinical Trial.
169 results